Angitia Biopharmaceuticals

Anzisin Organisms Innovation, also known as Anzi Sein, is a pioneering biotechnology startup founded in 2018. It operates primarily in Guangzhou, China, and California, USA. The company is dedicated to the research and development of innovative drugs for severe musculoskeletal disorders, including diseases affecting bones, joints, and muscles.

Anzi Sein's business model revolves around the development of new drugs and treatment programs. Their team, rich in experience and scientific insights, is committed to creating more effective and safe treatment options for patients suffering from motor system diseases. They generate revenue by developing and selling these innovative drugs.

The company's leadership includes experienced professionals like Lee Mu Woo, the former Chief Operating Officer of the Mint Angel Fund, a fund dedicated to investing in innovative drugs and technology. Lee Mu Woo's experience also includes organizing value assessment and development strategies for early clinical trials in China and managing clinical projects for neurosynthetic and ophthalmological projects.

In 2022, Anzi Sein is focusing on cutting-edge innovations to benefit people with severe musculoskeletal disorders. Their work is expected to have a significant impact on the biotechnology and healthcare market, particularly in the field of musculoskeletal disease treatment.

Keywords: Biotechnology, Drug Research, Musculoskeletal Disorders, Innovative Treatment, Motor System Diseases, Clinical Trials, Value Assessment, Development Strategy, Neurosynthetic Projects, Ophthalmological Projects.